Subtype
Malignant Exocrine Pancreas Neoplasm
CI-CAN-00003152Explore in graph →
361 active trials5 approved drugs27 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00003152Explore in graph →
Clinical trials
931 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (136)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05708599 | A Study to Compare Tissue and Liquid Biopsies in People With Different Types of Cancer | active not recruiting | N/A | 102 | Boehringer IngelheimINDUSTRY | 1 | Jan 21, 2026 | clinicaltrials |
| NCT07328607 | Outcomes After Laparoscopic Versus Open Pancreaticoduodenectomy | recruiting | N/A | 90 | Minia UniversityOTHER | 1 | Jan 21, 2026 | clinicaltrials |
| NCT07348107 |
| ATRA and SDK002 in Combination With Chemotherapy and Anti-PD-1 Inhibitor in Patients With Advanced Pancreatic Ductal Adenocarcinoma.(ATARI-PDAC) |
| not yet recruiting |
| Phase 1 |
| 10 |
| Daniel BreadnerOTHER |
| 1 |
| Jan 16, 2026 |
| clinicaltrials |
| NCT07342231 | FAPi PET in Pancreatic Ductal Adenocarcinoma(FAP-1) | recruiting | — | 60 | Tata Memorial HospitalOTHER_GOV | 1 | Jan 15, 2026 | clinicaltrials |
| NCT04539808 | NeoOPTIMIZE: Early Switching of mFOLFIRINOX or Gemcitabine/Nab-Paclitaxel Before Surgery for the Treatment of Resectable, Borderline Resectable, or Locally-Advanced Unresectable Pancreatic Cancer | active not recruiting | Phase 2 | 42 | OHSU Knight Cancer InstituteOTHER | 1 | Jan 14, 2026 | clinicaltrials |
| NCT03977233 | Tumor Subtypes in Subjects on FOLFIRINOX With Non-Metastatic Pancreatic Cancer | recruiting | Phase 2 | 45 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Jan 13, 2026 | clinicaltrials |
| NCT05651022 | Study of DECOY20 With or Without Tislelizumab in Patients With Advanced Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 120 | Indaptus Therapeutics, IncINDUSTRY | 1 | Jan 13, 2026 | clinicaltrials |
| NCT05679674 | Stereotactic Body Radiation and Tumor Treating Fields for Locally Advanced Pancreas Cancer | recruiting | N/A | 48 | Baptist Health South FloridaOTHER | 1 | Jan 12, 2026 | clinicaltrials |
| NCT06073431 | LOTUS-CC: An Observational Research Study to Uncover Subtypes of Cancer Cachexia(LOTUS) | recruiting | — | 800 | University of RochesterOTHER | 1 | Jan 9, 2026 | clinicaltrials |
| NCT06115499 | The PLATINUM Trial: Optimizing Chemotherapy for the Second-Line Treatment of Metastatic BRCA1/2 or PALB2-Associated Metastatic Pancreatic Cancer | active not recruiting | Phase 2 / Phase 3 | 10 | Alliance for Clinical Trials in OncologyOTHER | 1 | Jan 7, 2026 | clinicaltrials |
| NCT06693986 | Adenovirus (RGDCRAdCOX2F) | recruiting | Phase 1 | 18 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Jan 7, 2026 | clinicaltrials |
| NCT06999187 | A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas | recruiting | Phase 1 | 96 | Dren BioINDUSTRY | 1 | Jan 7, 2026 | clinicaltrials |
| NCT05336266 | A Feasibility Study of Ketorolac Treatment for Cachexia in Patients With Advanced Pancreatic Ductal Adenocarcinoma(KetoROCX) | active not recruiting | Early Phase 1 | 28 | Andrew Hendifar, MDOTHER | 1 | Jan 6, 2026 | clinicaltrials |
| NCT04146298 | Mutant KRAS G12V-specific TCR Transduced T Cell Therapy for Advanced Pancreatic Cancer | recruiting | Phase 1 / Phase 2 | 30 | Changhai HospitalOTHER | 1 | Dec 24, 2025 | clinicaltrials |
| NCT07301229 | A Phase II Clinical Study to Evaluate HLX43 in Subjects With Advanced Pancreatic Cancer | not yet recruiting | Phase 2 | 100 | Shanghai Henlius BiotechINDUSTRY | 0 | Dec 24, 2025 | clinicaltrials |
| NCT07262957 | Preventing Postoperative Complications in Patients Undergoing High-risk Pancreatoduodenectomy With a Bundle Approach Including Hydrocortisone, Octreotide, and the Teres Ligament Patch (PANENCA)(PANENCA) | recruiting | Phase 4 | 400 | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)OTHER | 1 | Dec 22, 2025 | clinicaltrials |
| NCT07284277 | TTFields and Chemotherapy in Metastatic Pancreatic Adenocarcinoma (mPDAC) | recruiting | Phase 1 / Phase 2 | 30 | Clinica Universidad de Navarra, Universidad de NavarraOTHER | 1 | Dec 16, 2025 | clinicaltrials |
| NCT06943521 | A Study of MT-4561 in Patients With Various Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 27 | Tanabe Pharma America, Inc.INDUSTRY | 2 | Dec 11, 2025 | clinicaltrials |
| NCT07269626 | PULSAR in Systemic Therapy for Pancreatic Cancer | recruiting | Phase 2 | 47 | Samsung Medical CenterOTHER | 1 | Dec 8, 2025 | clinicaltrials |
| NCT04570943 | Sequential Treatment With GEMBRAX and Then FOLFIRINOX Followed by Stereotactic MRI-guided Radiotherapy in Patients With Locally Advanced Pancreatic Cancer(GABRINOX-ART) | recruiting | Phase 2 | 103 | Institut du Cancer de Montpellier - Val d'AurelleOTHER | 1 | Dec 5, 2025 | clinicaltrials |
| NCT04002479 | Alpha Radiation Emitters Device for the Treatment of Advanced Pancreatic Cancer | active not recruiting | N/A | 37 | Alpha Tau Medical LTD.INDUSTRY | 1 | Dec 2, 2025 | clinicaltrials |
| NCT06333314 | Dostarlimab for Locally Advanced or Metastatic Cancer (Non-colorectal/Non-endometrial) With Tumor dMMR/MSI(Pan-MSI-ACSE) | recruiting | Phase 2 | 120 | UNICANCEROTHER | 1 | Dec 2, 2025 | clinicaltrials |
| NCT07232810 | Prognostic Outcomes of Total Mesopancreas Excision for Pancreatic Head Cancer(TMpE) | recruiting | N/A | 90 | Minia UniversityOTHER | 1 | Dec 2, 2025 | clinicaltrials |
| NCT07259590 | A Study of GFH375 Combined With Cetuximab or Chemotherapy in Participants With Solid Tumors Harboring KRAS G12D Mutation | recruiting | Phase 1 / Phase 2 | 126 | Genfleet Therapeutics (Shanghai) Inc.INDUSTRY | 1 | Dec 2, 2025 | clinicaltrials |
| NCT03983954 | Naptumomab Estafenatox in Combination With Durvalumab in Subjects With Selected Advanced or Metastatic Solid Tumor, Including a Cohort Expansion in Esophageal Cancer. | active not recruiting | Phase 1 | 120 | NeoTX Therapeutics Ltd.INDUSTRY | 2 | Nov 28, 2025 | clinicaltrials |
| NCT02921022 | Study Of Gemcitabine, Nab-paclitaxel, PEGPH20 and Rivaroxaban for Advanced Pancreatic Adenocarcinoma | active not recruiting | N/A | 110 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Nov 26, 2025 | clinicaltrials |
| NCT07241663 | Surgery for Locally Unresectable Pancreatic Cancer(ROBIN) | recruiting | — | 150 | Azienda Ospedaliera di PadovaOTHER | 1 | Nov 26, 2025 | clinicaltrials |
| NCT06132087 | PROACTIVE: Surgical Resection Outcomes in Locally Advanced and Unresectable Pancreatic Cancer After Neoadjuvant Chemotherapy | active not recruiting | N/A | 2 | University of Southern CaliforniaOTHER | 1 | Nov 25, 2025 | clinicaltrials |
| NCT07106827 | A Study of GV20-0251 in Advanced or Refractory Solid Tumors | recruiting | Phase 1 | 10 | West China HospitalOTHER | 1 | Nov 24, 2025 | clinicaltrials |
| NCT07241676 | Early Recurrence After Surgery for Pancreatic Cancer(POCEMON BLUE) | enrolling by invitation | — | 500 | Azienda Ospedaliera di PadovaOTHER | 1 | Nov 21, 2025 | clinicaltrials |
| NCT04902352 | The DISSECT Study: Effect of Peri-aDventItial SMA diSsECtion on Margin sTatus During Pancreaticoduodenectomy for Resectable Pancreatic Cancer | active not recruiting | N/A | 102 | University Hospital Birmingham NHS Foundation TrustOTHER | 1 | Nov 18, 2025 | clinicaltrials |
| NCT07233850 | A Phase II Clinical Study Evaluating SSGJ-706 in Combination Therapy for Advanced Gastrointestinal Cancers | not yet recruiting | Phase 2 | 300 | Shenyang Sunshine Pharmaceutical Co., LTD.INDUSTRY | 1 | Nov 18, 2025 | clinicaltrials |
| NCT06396091 | A Study of Zolbetuximab With Chemotherapy in Adults With Pancreatic Cancer | active not recruiting | Phase 1 | 12 | Astellas Pharma Global Development, Inc.INDUSTRY | 1 | Nov 13, 2025 | clinicaltrials |
| NCT06600906 | Hyperpolarized 13C MRI to Predict Response in Pancreatic Cancer | recruiting | — | 70 | University of California, San FranciscoOTHER | 1 | Nov 12, 2025 | clinicaltrials |
| NCT04821284 | Sonoporation and Chemotherapy for the Treatment of Pancreatic Cancer | active not recruiting | Phase 1 / Phase 2 | 120 | Flemming ForsbergOTHER | 2 | Nov 4, 2025 | clinicaltrials |
| NCT06984562 | Adaptive Radiation for Locally Advanced Unresectable Pancreatic Cancer | recruiting | N/A | 16 | Fox Chase Cancer CenterOTHER | 1 | Oct 29, 2025 | clinicaltrials |
| NCT04888312 | Safety and Efficacy of Mitazalimab in Combination With Chemotherapy in Pancreatic Cancer Patients(OPTIMIZE-1) | active not recruiting | Phase 1 / Phase 2 | 94 | Alligator Bioscience ABINDUSTRY | 3 | Oct 8, 2025 | clinicaltrials |
| NCT03245541 | Radiation Therapy in Combination With Durvalumab for People With Pancreatic Cancer | active not recruiting | Phase 1 / Phase 2 | 18 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Oct 7, 2025 | clinicaltrials |
| NCT03492671 | Testing the Combination of Two Approved Chemotherapy Drugs and Radiation Prior to Surgery in Localized Pancreatic Cancer | recruiting | Phase 2 | 30 | Loma Linda UniversityOTHER | 1 | Oct 2, 2025 | clinicaltrials |
| NCT04361708 | Safety of Combining Irinotecan With 5-FU, Leucovorin/Folinic Acid, Oxaliplatin, and Docetaxel Chemotherapies(I-FLOAT) | recruiting | Phase 1 | 54 | University of ChicagoOTHER | 1 | Oct 1, 2025 | clinicaltrials |
| NCT06182072 | ProAgio in Pancreatic Ductal Adenocarcinoma (PDAC) | recruiting | Phase 1 | 46 | ProDa BioTech, LLCINDUSTRY | 1 | Oct 1, 2025 | clinicaltrials |
| NCT07198321 | A Single-Arm, Open-Label, Multicenter Phase I/II Clinical Study of GFH276 in Patients With RAS-Mutant Advanced Solid Tumors | not yet recruiting | Phase 1 / Phase 2 | 450 | Genfleet Therapeutics (Shanghai) Inc.INDUSTRY | 1 | Sep 30, 2025 | clinicaltrials |
| NCT05116072 | Efficacy and Safety of TPIAT for Resectable Adenocarcinoma of the Pancreas Region at High Risk of Postoperative Fistula(TPIAT-01) | recruiting | Phase 1 / Phase 2 | 36 | University Hospital, LilleOTHER | 1 | Sep 25, 2025 | clinicaltrials |
| NCT07183280 | Multicentric Database for Solid Pseudopapillary Neoplasm of the Pancreas(SPN) | recruiting | — | 2,000 | Fudan UniversityOTHER | 1 | Sep 19, 2025 | clinicaltrials |
| NCT07155525 | Tissue Adhesive Glue Modified Cyanoacrylate (Glubran® 2) in Soft Pancreas(NBCA-MS) | recruiting | Phase 3 | 194 | Minia UniversityOTHER | 1 | Sep 18, 2025 | clinicaltrials |
| NCT06831136 | Endoscopic Ultrasound Radiofrequency Ablation and Immunotherapy Pembrolizumab for Locally Advanced Unresectable and Metastatic Pancreatic Duct Adenocarcinoma(PANCARDINAL-2) | recruiting | Phase 2 | 24 | The University of Texas Health Science Center, HoustonOTHER | 1 | Sep 10, 2025 | clinicaltrials |
| NCT05209074 | Ivosidenib + mFOLFIRINOX in Patients With Resectable Pancreatic Adenocarcinoma | active not recruiting | Phase 1 | 16 | Case Comprehensive Cancer CenterOTHER | 1 | Sep 5, 2025 | clinicaltrials |
| NCT05585320 | A Phase 1/2a Study of IMM-1-104 in Participants With Advanced or Metastatic Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 209 | Immuneering CorporationINDUSTRY | 1 | Sep 2, 2025 | clinicaltrials |
| NCT06728358 | The Future Management of Patients With Neoplasms of the Gastro-intestinal Tract(SOCRATE) | active not recruiting | N/A | 300 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 | Aug 26, 2025 | clinicaltrials |
| NCT05470920 | Genetic Testing Decision Aid | recruiting | N/A | 350 | Massachusetts General HospitalOTHER | 1 | Aug 13, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Jan 21, 2026source: clinicaltrials